In clinical samples, the USP10 levels were correlated with the IGF2BP1 and CPT1A levels in BC tissues, and BC patients with high levels of USP10, IGF2BP1, and CPT1A had the worst outcome. This evidence concerns the gene USP10 and breast cancer.